Table 6 Antimicrobial effect of PLNC8 αβ with antibiotics against resistant strains of Staphylococcus.
Antimicrobial agent | MRSA | S. epidermidis 126* | S. epidermidis 157* | ||||||
|---|---|---|---|---|---|---|---|---|---|
MIC | MBC | ΣFIC | MIC | MBC | ΣFIC | MIC | MBC | ΣFIC | |
L-PLNC8 αβ (µM) | 12.5 | 25 | 12.5 | 50 | 12.5 | >50 | |||
Vancomycin (µg/ml) | 1.5 | 3.1 | 3.1 | 3.1 | 6.25 | 6.25 | |||
Vancomycin/L-PLNC8 αβ (10 µM) | <0.097 | 0.39 | <0.097 | 0.78 | 6.25 | 6.25 | |||
Vancomycin/L-PLNC8 αβ (5 µM) | <0.097 | 0.78 | 1.00 | <0.097 | 0.78 | 0.38 | 6.25 | 6.25 | 1.01 |
Teicoplanin (µg/ml) | 0.78 | 3.1 | 3.1 | 6.25 | 12.5 | 25 | |||
Teicoplanin/L-PLNC8 αβ (10 µM) | <0.097 | 0.39 | <0.097 | 0.39 | 12.5 | 25 | |||
Teicoplanin/L-PLNC8 αβ (5 µM) | <0.097 | 0.78 | 0.75 | <0.097 | 0.39 | 0.38 | 12.5 | 25 | 1.01 |
